πŸ‡ΊπŸ‡Έ FDA
Patent

US 9994547

Heteroarylamide inhibitors of TBK1

granted A61KA61K31/497A61P

Quick answer

US patent 9994547 (Heteroarylamide inhibitors of TBK1) held by Takeda Pharmaceutical Company Limited expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/497, A61P, A61P1/00, A61P13/00